regorafenib
Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher
Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge
Actionable Insights Powered by AI
Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge